VI-TWEL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VI-TWEL is a small-molecule injectable product approved by Bayer in 1949. Generic name and mechanism of action are not publicly disclosed in available data. The drug is administered via injection and serves an undisclosed indication.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a contracting team focused on maximizing remaining exclusivity period rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to VI-TWEL, reflecting its mature, legacy status within the Bayer portfolio. Roles on this product are typically focused on operational efficiency and managed decline rather than launch or growth.
Brand ManagerField Sales
Worked on VI-TWEL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.